IPI-504 is an investigational drug that targets the protein Hsp90, which is important for cancer growth. Everolimus is a drug approved for kidney cancer, but its use for treating lung cancer is considered investigational. Everolimus inhibits another protein which fuels cancer growth, called mTOR.
In this study, researchers want to find the highest safe dose of IPI-504 and everolimus that can be given together in patients with non-small cell lung cancer (NSCLC) whose tumors have a mutation in the KRAS (phase IB portion of the study), and to see if this drug combination is effective for fighting this cancer (phase II portion). Laboratory studies have found that IPI-504 plus everolimus causes cancer cells to die and tumors to shrink.
Investigators also want to know what distinguishes patients who respond to treatment from those who do not. To determine this, they will look at patients’ genes in tumor and blood samples and compare them between responders and non-responders.